<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01144039</url>
  </required_header>
  <id_info>
    <org_study_id>VI_echo_01_2006</org_study_id>
    <nct_id>NCT01144039</nct_id>
  </id_info>
  <brief_title>Glutamate and Diastolic Function in Patients Undergoing Aortic Valve Repair</brief_title>
  <official_title>Glutamate Infusion in Hypertrophied Ventricle After Aortic Valve Replacement - a Randomized Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Vienna</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Vienna</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Purpose: The effect of intravenous glutamate infusion on myocardial diastolic function and
      overall hemodynamics were studied in patients undergoing elective aortic valve replacement
      with severe aortic stenosis and associated left ventricular hypertrophy .

      Methods: 25 patients will be included in this double-blind randomized placebo-controlled
      study. Glutamate was administered intravenously immediately after aortic cross-clamp release.
      The patients receive either a low dose of 30mg kg-1 h-1 (LG-group) or high dose of 60 mg kg-1
      h-1 (HG-group) or placebo (P-group) at a rate of 3.3ml kg-1h-1 for 2h. Transesophageal
      echocardiography (TEE) is used to measure diastolic and systolic ventricular function before
      sternotomy (T0), and 2h (T2), 3h (T3) and 6h (T4) after release of cross clamp. Additionally
      routine hemodynamic parameters are measured intraoperatively.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2006</start_date>
  <completion_date type="Actual">September 2008</completion_date>
  <primary_completion_date type="Actual">November 2007</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>flow propagational velocity</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Isovolumic relaxation time</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>E-velocity</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>A-velocity</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>E/A ratio</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>ejection fraction</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cardiac output</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mitral ring motion</measure>
  </secondary_outcome>
  <enrollment type="Actual">27</enrollment>
  <condition>Hypertrophy, Left Ventricular</condition>
  <condition>Aortic Stenosis</condition>
  <condition>Myocardial Ischemia</condition>
  <condition>Cardiopulmonary Bypass</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LG-group</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HG-group</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo-group</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  severe aortic stenosis

          -  left ventricular hypertrophy of more than 10mm IVS thickness

          -  normal ejection fraction

          -  SR

        Exclusion Criteria:

          -  moderately or severely reduced systolic left ventricular function (ejection fraction
             &lt;30%)

          -  atrial fibrillation or flutter

          -  intolerance to glutamate.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Clin. Dept. of Cardiothoracic and Vascular Anaesthesia &amp; Intensive Medicine, Medical University of Vienna, Vienna General Hospital</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>September 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 14, 2010</study_first_submitted>
  <study_first_submitted_qc>June 14, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 15, 2010</study_first_posted>
  <last_update_submitted>June 15, 2010</last_update_submitted>
  <last_update_submitted_qc>June 15, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 16, 2010</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Aortic Valve Stenosis</mesh_term>
    <mesh_term>Hypertrophy</mesh_term>
    <mesh_term>Hypertrophy, Left Ventricular</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

